Betmiga

Betmiga Overdosage

mirabegron

Manufacturer:

Astellas

Distributor:

Zuellig
Full Prescribing Info
Overdosage
Mirabegron (Betmiga) has been administered to healthy volunteers at single doses up to 400 mg. At this dose, adverse events reported included palpitations (1 of 6 subjects) and increased pulse rate exceeding 100 beats per minute (bpm) (3 of 6 subjects). Multiple doses of Mirabegron (Betmiga) up to 300 mg daily for 10 days showed increases in pulse rate and systolic blood pressure when administered to healthy volunteers.
Treatment for overdose should be symptomatic and supportive. In the event of overdose, pulse  rate, blood pressure, and ECG monitoring is recommended.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in